Effectiveness of Different Antimicrobial Strategies for Staphylococcal Prosthetic Joint Infection: Results From a Large Prospective Registry-Based Cohort Study

Henk Scheper,1,6 Robert J. P. van der Wal,1 Rachid Mahdad,2 Stefan Keizer,3 Nathalie M. Delfos,5 Joris C. T. van der Lugt,6 Karin Ellen Veldkamp,7 Peter A. Nolte,9 Masja Leendertse,6 Luc B. S. Gelinck,10 Femke P. N. Mollema,10 Emile F. Schippers,1,10 Hanke G. Wattel-Louis,10 Leo G. Visser,1 Rob G. H. H. Nelsens,4 and Mark G. J. de Boer1

1Department of Infectious Diseases, Leiden University Medical Centre, Leiden, The Netherlands, 2Department of Orthopaedics, Leiden University Medical Centre, Leiden, The Netherlands, 3Department of Orthopaedic Surgery, Alrijne Hospital, Leiderdorp, The Netherlands, 4Department of Orthopaedic Surgery, Haaglanden Medical Centre, The Hague, The Netherlands, 5Department of Infectious Microbiology, Leiden University Medical Centre, Leiden, The Netherlands, 6Department of Orthopaedic Surgery, Reinier Haga Orthopedic Center, The Hague, The Netherlands, 7Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands, 8Department of Orthopaedic Surgery, Spaarne Gasthuis, Hoofddorp, The Netherlands, 9Department of Medical Microbiology, Alrijne Hospital, Leiderdorp, The Netherlands, 10Department of Internal Medicine, Haaglanden Medical Centre, The Hague, The Netherlands, 11Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands, and 12Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands

Background. Treatment of staphylococcal prosthetic joint infection (PJI) usually consists of surgical debridement and prolonged rifampicin combination therapy. Tailored antimicrobial treatment alternatives are needed due to frequent side effects and drug-drug interactions with rifampicin combination therapy. We aimed to assess the effectiveness of several alternative antibiotic strategies in patients with staphylococcal PJI.

Methods. In this prospective, multicenter registry-based study, all consecutive patients with a staphylococcal PJI, treated with debridement, antibiotics and implant retention (DAIR) or 1-stage revision surgery between January 1, 2015 and November 3, 2020, were included. Patients were treated with a long-term rifampicin combination strategy (in 2 centers) or a short-term rifampicin combination strategy (in 3 centers). Antimicrobial treatment strategies in these centers were defined before the start of the registry. Patients were stratified in different groups, depending on the used antimicrobial strategy. Cox proportional hazards models were used to compare outcome between the groups.

Results. Two hundred patients were included and stratified in 1 long-term rifampicin group (traditional rifampicin combination therapy) or 1 of 3 short-term rifampicin groups (clindamycin or flucloxacillin or vancomycin monotherapy, including rifampicin for only 5 postoperative days). Adjusted hazard ratios (aHRs) for failure in patients treated with short-term rifampicin and either flucloxacillin or clindamycin were almost equal to patients treated with long-term rifampicin combination therapy (aHR = 1.21; 95% confidence interval, 0.34–4.40).

Conclusions. A short-term rifampicin strategy with either clindamycin or flucloxacillin and only 5 days of rifampicin was found to be as effective as traditional long-term rifampicin combination therapy. A randomized controlled trial is needed to further address efficacy and safety of alternative treatment strategies for staphylococcal PJI.

Keywords. antimicrobial strategies; DAIR; rifampicin combination treatment; staphylococcal prosthetic joint infection; vancomycin;

A prosthetic joint infection (PJI) is a serious complication occurring in 1%–2% of patients with a joint arthroplasty resulting in prolonged hospitalization, impaired mobility, and long-term antibiotic treatment [1, 2]. Most PJIs are caused by staphylococci, most of which are highly susceptible for rifampicin, clindamycin, and flucloxacillin (methicillin-resistant Staphylococcus aureus is virtually absent in The Netherlands) [3]. Treatment of acute PJI consists of thorough surgical debridement combined with antimicrobial therapy. Adequate debridement is of utmost importance because the biofilm that has been formed on the surface of the implant needs to be removed as much as possible to enable cure. Antimicrobial therapy consists of intravenous (IV) antibiotics for up to 2 weeks followed by targeted oral antimicrobial therapy [4]. For staphylococcal PJI, rifampicin and fluoroquinolone combination therapy is advocated by most national guidelines. However, its use is hampered in practice by drug-drug interactions and significant side effects. This underscores the need for safe and effective alternative antimicrobial regimens for PJI [5, 6]. Furthermore, the evidence for this antibiotic strategy in
clinical studies for staphylococcal PJI is lacking [7, 8]. In addition, studies investigating tailored alternative strategies for rifampicin combination treatment are scarce [9, 10]. In 2015, a regional group of specialized centers for PJI decided to intensify collaboration and harmonized their local protocols for antimicrobial and surgical treatment. In those centers, several different antibiotic strategies, which were consistent within a center, were accepted as routine care to treat staphylococcal PJI after debridement, antibiotics and implant retention (DAIR) or 1-stage exchange: a long-term rifampicin strategy (consisting of 12 weeks rifampicin combination therapy) and several short-term rifampicin strategies, consisting of only 5 days of rifampicin combination treatment, started immediately postoperative, followed by clindamycin, flucloxacillin, or vancomycin monotherapy. The collaborating centers initiated a web-based quality registry to evaluate the outcome of PJI after implementation of this protocol. The main objective of this prospective study is to compare the effectiveness of long-term rifampicin combination treatment with several short-term rifampicin antimicrobial strategies for the treatment of staphylococcal PJI.

METHODS

Study Design

This multicenter, prospective, registry-based cohort study was conducted as part of the Prosthesis Protect Project. This prospective quality registry comprised 5 regional hospitals in the south-western area in the Netherlands that coordinated treatment for patients with PJI. A treatment protocol for PJI was written by all collaborators before data collection in the database. As for registration of data, all treatment decisions and deviations from the protocol were discussed during weekly multidisciplinary meetings (MDT) with orthopedic surgeons, infectious diseases physicians, and/or clinical microbiologists. Data were collected in a secured online database and double-checked by the coordinating investigator; discrepancies were resolved by consensus.

Patient Consent Statement

The study was approved by the institutional review board of Leiden University Medical Center with a waiver of written informed consent and conducted according to Dutch law and regulations regarding medical research. All patients with PJI were informed by their treating physician about the quality registry and were included in the database unless they opted out.

Data Collection and Treatment Protocol

For the current study, all patients aged 18 years or older with staphylococcal PJI treated with DAIR or 1-stage exchange between January 1, 2015 and November 3, 2020 were eligible for inclusion. Only these surgical strategies were included because the focus of this study is on the role of antimicrobial therapy in the context of retained or newly inserted implants in an infected area. Patients with polymicrobial PJI including staphylococci were also included. Patients with infected megaprostheses (eg, after tumor resections) were excluded. Prosthetic joint infection was defined in compliance with the Infectious Diseases Society of America (IDSA) guideline on PJI [4]. The diagnostic and debridement procedure was completely standardized between the centers (see Supplementary Table 1). Patients with acute PJI were treated with DAIR. One-stage exchange was performed in patients with chronic PJI. Empiric antimicrobial therapy for PJI was started after intraoperative cultures were taken.

Definitions

Prosthetic joint infection was defined as acute PJI when diagnosed within 3 weeks after onset of clinical symptoms or within 3 weeks after implantation or last revision of the implant. All other PJIs were defined as chronic PJI. For the current study, patients were also stratified in early acute PJI (within 3 weeks after arthroplasty or revision), early chronic PJI (between 3 weeks and 3 months after arthroplasty or revision), late chronic PJI (more than 3 months after arthroplasty or revision, caused by low-virulent microorganisms), and late acute PJI (more than 3 months after arthroplasty or revision, caused by virulent microorganisms; eg, S aureus). Cure was defined as absence of clinical symptoms of infection and a retained implant during at least 12 months follow up after antibiotic therapy was terminated AND if failure criteria were not met. Failure was defined as either (1) chronic suppressive antibiotic therapy with implant retention, (2) a second debridement after finishing antibiotic therapy, (3) the need for more than 2 debride-ments, (4) removal of the implant, or (5) PJI-related death. Secondary failures with other microorganisms were also counted as failure.

Empiric and Targeted Antimicrobial Strategy

In all centers, empiric antibiotic therapy after surgery consisted of flucloxacillin (6 gram IV/24 hours) plus an aminoglycoside until targeted therapy could be started, based on cultures and antibiotic sensitivity. The timing of the IV-to-oral switch was after 1–2 weeks. In 3 centers, rifampicin (600 mg twice daily) was added to empiric treatment for only 5 postoperative days, starting immediately postoperative [11]. For the purpose of this study, this was defined as a “short-term rifampicin” strategy. In this strategy, oral targeted therapy consisted of clindamycin (600 mg 3 times daily) or flucloxacillin (1000 mg 4 or 5 times a day), dependent on susceptibility, documented allergy, or intolerance. For flucloxacillin, an adequate absorption test was required, defined as a serum flucloxacillin concentration that increased at least 10 mg/L, 45 minutes or 90 minutes after an oral loading dose of 1000 mg [12]. If preferred treatment options were not available, alternative antibiotics were chosen, depending on the antibiogram. Total treatment
duration was between 6 and 12 weeks, based on the clinical and biochemical response, such as to be decided by the MDT.

In 2 remaining centers, patients with staphylococcal PJI were treated with long-term rifampicin combination therapy, the generally accepted standard-of-care treatment for staphylococcal PJI after DAIR [4]. Oral rifampicin (300 mg twice daily) was first added to intravenous treatment once antibiotic susceptibility for rifampicin was confirmed and the postoperative wound was dry. After 2 weeks, it was combined with levofloxacin for a fixed treatment duration of 12 weeks. The differences in timing and duration of rifampicin between the 2 clusters were defined in advance in the protocol, using hospital as an instrumental variable with patients being assigned to either a long-term or one of the short-term rifampicin strategies. For the purpose of this study, patients were classified in 5 groups: a rifampicin-based group, a flucloxacillin-based group, a clindamycin-based group, a vancomycin-based group, and a nondefined “other antibiotics” group consisting of patients who did not meet the criteria for the first 4 groups (Table 1).

Statistical Analysis
Clinical characteristics at baseline were summarized using descriptive statistics, stratified by antibiotic strategies. Differences between antibiotic groups were compared with \( \chi^2 \) testing for categorical variables, one-way analysis of variance for continuous variables, and Mann-Whitney U tests for nonnormally distributed continuous variables. Kaplan-Meier curves were constructed to report outcome by the different antibiotic groups. Patients were counted as failure if PJI was the direct cause of death. Patients were censored at the time of death if they died during follow up due to an event not related to PJI. A Cox proportional hazards regression model was used to investigate whether differences in outcome were associated with baseline differences between groups. Variables in the multivariate model were selected based on the univariate regression analysis. Results are reported as hazard ratios (HRs) with 95% confidence intervals (95% CIs). To prevent immortal time bias in the short-term rifampicin antibiotic groups and to focus on the targeted treatment phase for PJI, the minimal survival time required for inclusion in the survival analysis was defined as at least 15 days after debridement. SPSS Statistics for Windows was used (IBM SPSS Statistics for Windows, Version 25.0., Armonk, NY).

RESULTS

Of 493 patients currently registered in the database, 200 patients were included (Figure 1). Baseline clinical characteristics of the 5 antimicrobial strategy groups are summarized in Table 2. The proportion of \( S \) aureus PJI and bacteremia and were higher in the flucloxacillin-based group compared to the other groups \( (P < .05) \). Patients in the vancomycin-based and other antibiotics group had more polymicrobial PJI, including enterococci and corynebacteria. Follow-up data are summarized in Table 3. According to the protocol, treatment duration with rifampicin was only 5 days in the short-term rifampicin groups. Total antimicrobial treatment duration was longer in the long-term rifampicin group (12 weeks) compared to the short-term rifampicin groups (8 weeks) \( (P = .006) \). Four patients (12%) in the rifampicin-based group received rifampicin for only 3–6 weeks. In the flucloxacillin group, cure rate was 88% (14 of 16) in patients who continued with oral flucloxacillin after 2 weeks intravenous flucloxacillin and 74% (23 of 31) in patients with prolonged intravenous flucloxacillin (Table 3). In only 32% of failures, the same causative staphylococci could be cultured again.

The survival curves for the different antibiotic strategies are shown in Figure 2A. Cure rates in the clindamycin group (91%)
and the flucloxacillin group (79%) did not differ significantly from the rifampicin group (87%, \( P = .20 \)). Patients treated with vancomycin or not treated according to a predefined regimen had a worse outcome. Within the vancomycin-based group, success rates were lower for polymicrobial PJI with enterococci (\( P = .02 \)). Diabetes mellitus and duration of symptoms more than 3 weeks were significantly associated with failure in the univariate Cox regression model (Table 4 and Supplementary Figure 1). Late acute PJI, enterococcal PJI, and bacteremia were associated with a worse outcome, although not statistically significant (Table 4). The adjusted hazard ratios for failure in the clindamycin group (HR = 0.84; 95% CI, 0.20–3.55), the flucloxacillin group (HR = 2.21; 95% CI, 0.60–8.17), or the combined clindamycin and flucloxacillin group (HR = 1.21; 95% CI, 0.34–4.40) remained equal to the rifampicin-based group.

**DISCUSSION**

There is an urgent need for alternative antimicrobial strategies for staphylococcal PJI because the current strategy with long-term rifampicin-based combination therapy is associated with significant side effects and interactions [5, 6, 13]. In the current study, outcome of PJI after DAIR or 1-stage exchange was not statistically different between patients treated with long-term rifampicin combination therapy and patients treated with clindamycin or flucloxacillin monotherapy including only 5 days of rifampicin combination therapy. Moreover, treatment duration was 4 weeks shorter in the clindamycin-based and flucloxacillin-based groups. After correction for confounding covariates that were not evenly distributed across the groups at baseline, the outcomes in a multivariate Cox proportional hazards model did not change. Diabetes mellitus, bacteremia, and a longer duration of symptoms (more than 3 weeks) were independent risk factors for failure.

**Clindamycin Monotherapy for Staphylococcal Prosthetic Joint Infection**

Clindamycin is known to have an excellent bioavailability and penetrates well into synovial fluid and bone [14]. Reasonable outcome with clindamycin therapy for staphylococcal PJI has been incidentally published before, but this is the first study reporting the systematic use of clindamycin monotherapy [15, 16]. Physicians in the short-term rifampicin strategy centers had no specific preference for either clindamycin or flucloxacillin, except that clindamycin was easier to use due to a lower pill burden. The choice for either clindamycin or flucloxacillin was completely unbiased in patients with clindamycin-resistant staphylococci or an inadequate flucloxacillin absorption test, but this was the case in only a minority of patients [12]. How should we interpret the finding that 8 weeks of clindamycin-based treatment, including 5 initial days of rifampicin, was equivalent to 12 weeks rifampicin combination therapy and superior to flucloxacillin? Confounding by indication is the most likely explanation because in patients who needed a second debridement or who had persisting high inflammatory parameters, the IV-oral switch from flucloxacillin to clindamycin (or oral flucloxacillin) was postponed on purpose (as illustrated in Table 3 with longer IV treatment duration and more second DAIRs in the flucloxacillin-group). Consequently, more patients with a worse course met the criteria for the flucloxacillin-based group, leading to selection bias in favor of the clindamycin-based group. Correction for this confounding was performed by combining both groups, resulting in a cure of 85% in the combined group, which was equivalent to the rifampicin group (87%, \( P = .77 \)) (Supplementary Figure 4).

---

**Figure 1.** Flowchart of inclusion for current study. DAIR, debridement, antibiotics and implant retention; PJI, prosthetic joint infection.
| Characteristics | All | Rifampicin Based | Clindamycin Based | Fluoroxyclacin Based | Vancomycin Based | All Other Strategies | P Value |
|-----------------|-----|-----------------|-----------------|---------------------|----------------|--------------------|---------|
| N patients      | 200 | 23              | 56              | 47                  | 26             | 48                 |         |
| General Characteristics |       |                 |                 |                     |                |                    |         |
| Male sex (%)    | 95   | 48              | 52              | 23 (49)             | 10 (39)       | 22 (46)            | .86     |
| Age in years (SE mean) | 70.3 (0.9) | 68.8 (2.9) | 67.2 (1.7) | 70.1 (2.1) | 72.3 (2.1) | 73.6 (1.7) | .12     |
| Joint           |      |                 |                 |                     |                |                    |         |
| Hip             | 131  | 6 (61)          | 37 (66)         | 30 (64)             | 20 (77)       | 30 (63)            | .76     |
| Total hip arthroplasty | 109 (85) | 12 (86) | 32 (87) | 28 (93) | 15 (75) | 22 (73) | .70     |
| Hemiarthroplasty | 20   | 2 (14)          | 5 (13)          | 2 (7)               | 5 (25)        | 8 (27)             |         |
| Total knee arthroplasty | 63 (32) | 7 (30) | 17 (32) | 16 (34) | 6 (23) | 16 (33) | .90     |
| Shoulder        | 5 (2.5) | 2 (9) | 1 (2) | 1 (2) | 0 | 1 (2) |         |
| Elbow           | 1 (0.5) | 0 | 0 | 0 | 1 (2) |         |         |
| Previous revision | 52 (26.0) | 8 (35) | 11 (20) | 9 (19) | 5 (22) | 19 (40) | .08     |
| Previous PJl of same implant | 10 (5.0) | 0 | 1 (2) | 0 | 5 (10) | .09     |
| Comorbidities   |      |                 |                 |                     |                |                    |         |
| Diabetes, n (%) | 48   | 24.0 (17)       | 5 (22)          | 12 (21)             | 10 (21)       | 9 (35)             | 12 (25) | .73     |
| Chronic kidney disease (eGFR <60 mL/min) | 21 (10.6) | 3 (13) | 4 (7) | 4 (9) | 4 (15) | 6 (13) | .73     |
| Rheumatoid arthritis | 13 (6.5) | 3 (13) | 2 (4) | 3 (6) | 1 (4) | 4 (8) | .57     |
| Immunosuppressants | 15 (7.5) | 2 (9) | 3 (5) | 6 (13) | 0 | 4 (8) | .35     |
| Malignancy      | 14 (7.0) | 0 | 6 (11) | 3 (6) | 1 (4) | 4 (8) | .49     |
| Reported smoking (n=160) | 26 (13.0) | 9 (39) | 6 (11) | 2 (4) | 3 (12) | 6 (13) |         |
| Body mass index (mean, SE) | 30 (0.42) | 28 (1.3) | 30 (0.8) | 29 (1.0) | 30 (1.0) | 30 (0.8) | .57     |
| Clinical Presentation |      |                 |                 |                     |                |                    |         |
| Bacteremia      | 25 (12.5) | 4 (17) | 4 (7) | 11 (23) | 0 | 6 (13) | .02     |
| Antibiotic pretreatment | 31 (15.5) | 3 (13) | 10 (18) | 7 (15) | 2 (8) | 9 (19) |         |
| Reported Symptoms |      |                 |                 |                     |                |                    |         |
| Fever >38.3°C   | 40 (20.0) | 5 (22) | 10 (18) | 16 (34) | 1 (4) | 8 (17) |         |
| Pain            | 107 (53.5) | 11 (48) | 32 (57) | 31 (66) | 8 (31) | 24 (50) |         |
| Redness         | 94 (47.0) | 5 (22) | 31 (55) | 21 (45) | 11 (42) | 26 (54) |         |
| Wound leakage   | 120 (60.0) | 16 (70) | 31 (55) | 22 (47) | 23 (89) | 28 (58) |         |
| Fistula         | 4 (2.0) | 0 | 3 (6) | 1 (4) | 1 (2) |         |         |
| Suppuration      | 25 (12.5) | 4 (17) | 5 (9) | 7 (15) | 3 (12) | 6 (13) |         |
| Laboratory Values |      |                 |                 |                     |                |                    |         |
| CRP (median, range) | 81 (1–585) | 86 (2–313) | 74 (3–443) | 157 (1–585) | 69 (10–342) | 100 (1–491) | .04     |
| ESR (median, range) | 49 (2–140) | 53 (8–130) | 41 (7–120) | 53 (2–120) | 46 (4–140) | 58 (5–133) |         |
| Leukocytes (mean, SE) | 11.2 (0.3) | 11.1 (1.1) | 11.2 (0.5) | 11.9 (0.7) | 10.1 (1.2) | 11.1 (0.7) | .64     |
| Causative Microorganisms (n, %) |      |                 |                 |                     |                |                    |         |
| Staphylococcus aureus | 120 (60.0) | 13 (57) | 35 (63) | 39 (63) | 8 (31) | 25 (52) | .00     |
| Coagulase-negative staphylococci | 89 (45) | 11 (48) | 22 (39) | 9 (19) | 20 (77) | 27 (56) | .00     |
| Staphylococcus epidermidis | 64 (32) | 5 (22) | 12 (21) | 7 (15) | 19 (73) | 21 (44) |         |
| Staphylococcus lugdunensis | 13 (7) | 4 (17) | 3 (5) | 2 (4) | 0 | 4 (8) |         |
| Staphylococcus capitis | 8 (4) | 2 (9) | 6 (11) | 0 | 0 | 0 |         |
| Other CNS       | 8 (4) | 1 (4) | 4 (7) | 0 | 1 (4) | 2 (4) |         |
| Polymicrobial PJL | 70 (36) | 11 (48) | 11 (20) | 10 (21) | 15 (58) | 23 (48) | .00     |
| Staphylococci + streptococci | 15 (8) | 2 (9) | 0 | 2 (4) | 3 (12) | 8 (15.1) |         |
| Staphylococci + Gram negatives | 20 (10) | 4 (17) | 3 (5) | 3 (6) | 2 (8) | 8 (17) |         |
| Staphylococci + Cutibacterium acnes | 5 (3) | 0 | 2 (4) | 0 | 1 (4) | 2 (4) |         |
| Staphylococci + corynebacteria | 16 (8) | 1 (4) | 1 (2) | 4 (9) | 6 (23) | 4 (8) |         |
| Staphylococci + enterococci | 23 (12) | 3 (13) | 1 (2) | 2 (4) | 6 (23) | 11 (23) |         |
| Staphylococci + anaerobic bact. | 7 (4) | 0 | 1 (2) | 1 (2) | 3 (12) | 2 (4) |         |
| Classification PJL: 4 groups (n, %) |      |                 |                 |                     |                |                    |         |
| Early postoperative PJL (<3 weeks) | 94 (47) | 13 (57) | 22 (39) | 20 (43) | 19 (73) | 20 (42) | .13     |
| Early chronic PJL (3 weeks–3 months) | 53 (27) | 6 (26) | 19 (34) | 11 (23) | 5 (19) | 12 (25) | .13     |
Flucloxacillin Monotherapy for Staphylococcal Prosthetic Joint Infection

Clinical data regarding the use of flucloxacillin for bone and joint infections are scarce [17]. This study shows 78% success rates for staphylococcal PJI in the flucloxacillin-based group and an even higher success rate of 88% in the subgroup of patients treated with oral flucloxacillin monotherapy. This suggests that oral flucloxacillin may be an adequate treatment strategy for staphylococcal PJI. The results in this study are congruent with an earlier small cohort study by the same authors describing reasonable outcome for staphylococcal PJI with oral flucloxacillin and short-term addition of rifampicin [11]. However, the efficacy of oral flucloxacillin for targeted treatment of staphylococcal infections is limited by the need for adequate dosing and careful monitoring.

### Table 2. Follow Up and Treatment Outcome Characteristics of All Patients and After Stratification for Antibiotic Treatment Strategy

| Characteristics | All (n=200) | Rifampicin Based | Clindamycin Based | Flucloxacillin Based | Vancomycin Based | All Other Strategies | P Value |
|-----------------|------------|------------------|-------------------|---------------------|-----------------|---------------------|---------|
| N patients      | 200        | 23               | 56                | 47                  | 26              | 48                  |         |
| Antibiotic Strategy (Median Days, IQR) |            |                  |                   |                     |                 |                     |         |
| Duration antimicrobial treatment | 57 (6–765) | 94 (85–103) | 56 (40–62) | 41 (33–50) | 55 (15–131) | 53 (33–73) | .001   |
| Flucloxacillin i.v. | 11 (0–385) | 12 (2–22) | 13 (8–18) | 31 (18–44) | 3 (0–5) | 3 (0–6) |         |
| Flucloxacillin p.o. |            |                  |                   |                     |                 |                     |         |
| Duration rifampicin treatment | 5 (0–373) | 86 (78–94) | 5 (5–5) | 5 (4–5) | 5 (4–5–5.5) | 5 (4–6) | .000   |
| Time to start rifampicin | 0 (0–11) | 4 (2–6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | .000   |
| Surgical Treatment Strategy (n, %) |            |                  |                   |                     |                 |                     |         |
| DAIR            | 189 (94)   | 22 (96) | 51 (91) | 45 (96) | 25 (96) | 46 (96) | .78    |
| Reported head exchange hip | 20/122 (16) | 2/12 (17) | 1/33 (3) | 7/27 (26) | 4/19 (21) | 6/29 (21) |         |
| Reported liner exchange knee | 37/61 (61) | 5/7 (71) | 13/17 (76) | 7/16 (44) | 3/6 (50) | 9/15 (60) |         |
| One-stage revision procedure | 11 (6) | 1 (4) | 5 (9) | 2 (4) | 1 (4) | 2 (4) |         |
| Surgical Interventions During Treatment |            |                  |                   |                     |                 |                     |         |
| Re-DAIR needed | 86 (43) | 9 (39) | 13 (23) | 23 (49) | 16 (62) | 25 (52) | .005   |
| Time to re-DAIR (median days, range) | 16 (3–407) | 9 (3–14) | 18 (3–336) | 16 (5–152) | 23 (10–407) | 15 (5–358) |         |
| 1 Re-DAIR in cured patients | 36 | 6 | 5 | 12 | 7 | 6 |         |
| 2 Re-DAIRs in cured patients | 6 | 0 | 3 | 2 | 1 | 0 |         |
| Failure |            |                  |                   |                     |                 |                     |         |
| Failure or death due to PJI | 53 (27) | 3 (13) | 5 (9) | 10 (21) | 8 (31) | 27 (56) |         |
| Time to failure (days, range) | 84 (6–410) | 191 (103–274) | 154 (85–399) | 47 (20–397) | 33 (21–410) | 68 (6–381) |         |
| Confirmed relapse with same staphylococci | 17 (32) | 1/3 (33) | 3/5 (60) | 3/10 (30) | 1/8 (13) | 9 (33) |         |

### Table 3. Antibiotic Treatment Strategy Groups (n=200)

| Characteristics | Rifampicin Based | Clindamycin Based | Flucloxacillin Based | Vancomycin Based | All Other Strategies | P Value |
|-----------------|-----------------|------------------|---------------------|-----------------|---------------------|---------|
| Late chronic PJI (>3 months) | 18 (9) | 1 (4) | 8 (14) | 2 (4) | 1 (4) | 6 (13) | .03   |
| Hematogenous PJI | 35 (17) | 3 (13) | 7 (13) | 14 (30) | 1 (4) | 10 (21) |         |

Abbreviations: CNS, central nervous system; CRP, C-reactive protein; DAIR, debridement, antibiotics and implant retention; eGFR, estimated glomerular filtration rate; ESFR, erythrocyte sedimentation rate; PJI, prosthetic joint infection; SE, standard error.

aExact inclusion criteria for each antibiotic subgroup are defined in Table 1. All patients in the flucloxacillin, clindamycin, vancomycin, or “other” group were also treated with 5 days of rifampicin starting immediately postoperative after DAIR.

bAmoxicillin (n = 9), amoxicillin-clavulanic acid (n = 3), levofloxacin (n = 4), linezolid (n = 8), ceftriaxone (n = 3), doxycycline (n = 3), cotrimoxazole (n = 10), ciprofloxacin (n = 4).

©2022 Schepet al.
PJI should be further assessed in a large trial. In addition, a flucloxacillin absorption test is required to identify patients with inadequate oral absorption of flucloxacillin [12].

Rifampicin Combination Therapy for Staphylococcal Prosthetic Joint Infection

The effectivity of long-term rifampicin combination therapy in this study is in line with other studies reporting good outcome with this strategy [8, 18]. The strength of the current study is that 2 different and predefined strategies could be directly compared between centers, which minimized confounding by indication between the long-term and the short-term rifampicin-based groups. However, treatment may have varied in other ways not captured by the protocol because treatment teams between the participating centers were different. The outcome of staphylococcal PJI over time did not differ between centers with either a standard short-term or long-term rifampicin treatment strategy (Supplementary Figure 5). Most surgeons in participating hospitals were educated and trained in the same program. Due to later connection of long-term rifampicin treatment centers to the registry, fewer patients on long-term rifampicin could be included. However, given the high cure rate in the rifampicin-based group, this would likely lead to an overestimation rather than an underestimation of success rates in the rifampicin group. The results of this study are in line with 2 recent systematic reviews in which rifampicin-based strategies were not superior to nonrifampicin strategies [7, 8]. The rationale behind the immediate start of the 5-day rifampicin treatment in our region is that the need for a highly bactericidal drug is expected to be most crucial in the early postoperative period after debridement. Rifampicin kills bacteria, including intracellular staphylococci, at a fast rate [19]. Experimental animal models showed that 4 days of rifampicin combination therapy quickly eradicated implant-associated infections [20]. The RCT with 3–6 months of treatment with rifampicin was regarded as heavily underpowered to implement long-term rifampicin treatment in our region. Therefore, a 5-day treatment schedule with rifampicin was chosen to quickly reduce the bacterial load remaining around the implant as early as possible in the postoperative period. This should prevent new staphylococcal biofilm formation on the implant and therefore reduce the odds for a relapse. An important question that arises from our results is whether the first 5 days of rifampicin contributed at all to the high cure rates in the short-term rifampicin groups. This study cannot answer this question because patients were not treated without these 5 days of rifampicin. The attributive role of long-term rifampicin will be investigated in a large nationwide RCT in The Netherlands.

Duration of Antimicrobial Therapy

Median duration of antibiotic therapy was 4 weeks shorter in the flucloxacillin- and clindamycin-based groups compared to the rifampicin-based group but with equal cure rates. Success rates were similar after dividing the flucloxacillin- and clindamycin-based groups into 2 separate groups based on treatment duration. Success rate was 82.6% if treated for 6 weeks (median treatment duration 40 days) and 86.3% if treated for >6 weeks (median treatment duration 63 days, \( P = .75 \)). These results contradict the results of the recently published DATIPO trial in which 12 weeks of antimicrobial therapy was clearly superior to 6 weeks [21]. In the DATIPO trial, patients were randomized at the start of the study. In our cohort, the decision to stop antibiotic treatment in the short-term group was made in the sixth week of treatment, which has the advantage that the clinical course of the first
6 weeks could be considered (Table 1). Therefore, our data suggest, in line with other studies, that the decision to stop antimicrobial therapy after 6 weeks, based on a quickly improved clinical course, a normalized C-reactive protein, and after MDT discussion, may still be regarded as a safe strategy [21–24].

**Strengths and Limitations**

A major strength of this study is that several well defined strategies were compared. Comparing one well defined strategy (eg, rifampicin or clindamycin) with all other nondefined strategies (eg, nonrifampicin or nonclindamycin) will usually lead to bias in favor of the well defined strategy and may lead to unjustified rejection of equally good alternatives within that nondefined group (an example of this is shown in Supplementary Figure 2). One possibility to solve this is to define several well defined groups as was done in this study. However, confounding by indication can still be present in the well defined groups as discussed for the clindamycin and flucloxacillin groups. Of note, this study also contains a fifth “nondefined” group of patients, evenly present in all participating centers, with a worse outcome. Different treatment strategies within this group were very heterogeneous (Table 2).

To further strengthen the methodological quality of the study, patients with failure within 2 weeks after surgery (n = 10, evenly distributed among the centers) were excluded from survival analysis. This is because these patients were still on intravenous antibiotics and had not yet started one of the preferred treatment options. Patients with megaprostheses (used in malignancies) were also excluded to reduce bias. Furthermore, a second DAIR during treatment was not automatically considered a failure and resulted in cure in many patients (Table 3). If we would have defined all subsequent surgeries as failure, the overall cure rate would drop from 77% to 55% (Figure 2B). However, this drop-in cure rate would evenly affect cure regardless the duration of rifampicin treatment. These differences in cure show the importance of a uniform and clear-cut definition when comparing outcome between PJI studies. We suggest defining subsequent surgery only as a failure if a third debridement was needed or if surgery is needed after finishing antimicrobial therapy.

A limitation of the current study is the heterogeneity by also including patients with chronic PJI and patients with 1-stage revision surgery. We thought it was justified to do so because a DAIR can still be a good treatment option in patients with longer duration of symptoms, as reported recently [25]. Although patients with 1-stage revision surgery were treated with the same short-term or long-term rifampicin strategy in the different centers, the surgical strategy differs from that of a DAIR. Therefore, we repeated the survival analysis, excluding patients after 1-stage exchange. This did not affect outcome (Supplementary Figure 3).

To exclude that the results of this study may be explained by effects of other antibiotics that were used for pathogens in the patients with polymicrobial PJI, we performed an additional survival analysis including only the 130 patients with monobacterial staphylococcal PJI. This resulted in a limited increase in success rate in the vancomycin group (69%–72%) and no change of success rates in the rifampicin-, flucloxacillin-, and clindamycin-based groups, indicating that the activity against staphylococci was not caused by other antibiotics.

**CONCLUSIONS**

This study suggests that clindamycin or flucloxacillin monotherapy with only short-term induction therapy with rifampicin for 5 days might be considered as a reliable alternative to long-term rifampicin combination therapy. Although adjustment for confounding variables reduced bias as much as possible, the number of patients in the subgroups was still quite low. In future studies, researchers should assess whether adjunctive short-term induction therapy with rifampicin in patients

---

Table 4. Univariate and Multivariate Cox Proportional Hazards Model of Clinical Characteristics Associated With Failure

| Covariate                              | Univariate | Multivariate* |
|----------------------------------------|------------|---------------|
|                                        | HR 95% CI  | HR 95% CI     |
| Male sex                               | 1.35 .74–2.46 | …             |
| Revision before PJI                    | 1.48 .78–2.79* | 1.55 .79–3.03 |
| Knee PJI                               | 0.99 53–1.87  | …             |
| Corticosteroid use                     | 1.09 .34–3.53 | …             |
| DM                                     | 2.15 1.16–3.98* | 2.12 1.14–3.42 |
| RA                                     | 1.20 .37–3.89  | …             |
| *Staphylococcus aureus PJI*            | 0.89 .49–1.61  | …             |
| Bacteremia                             | 1.75 .78–3.93* | 2.66 1.09–6.48 |
| Duration of symptoms <3 weeks          | 0.46 23–94* | 0.37 .18–77   |
| Polymicrobial PJI                      | 0.98 .53–1.81  | …             |
| Enterooccci as copathogen              | 1.91 .89–4.12* | 1.48 .64–3.42 |
| Classification PJI                     | … …         | …             |
| Early postoperative                     | … …         | …             |
| Early chronic                          | 0.94 .44–2.01  | …             |
| Late chronic                           | 1.05 .36–3.08  | …             |
| Late acute (hematogenous)              | 1.80 .84–3.85  | …             |
| Long-term rifampicin strategy center   | 1.26 .53–2.98  | …             |
| Treatment strategy:                    | … …         | …             |
| Rifampicin based                       | … …         | Ref. …        |
| Either clindamycin or flucloxacillin   | 1.20 .35–4.15  | 1.21 .34–4.40 |
| Clindamycin based                      | 0.69 .16–2.87  | 0.84 .20–3.55 |
| Flucloxacillin based                   | 1.98 .54–7.19  | 2.21 .60–8.17 |
| Vancomycin based                       | 2.93 .78–11.06 | 3.68 .95–14.24 |
| Other strategy                         | 4.69 1.38–15.96 | 4.86 1.41–16.78 |
| Exchange of liner                      | 1.27 .65–2.50  | …             |

Abbreviations: CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; PJI, prosthetic joint infection; RA, rheumatoid arthritis; Ref., reference group.

*a* Included variables (•) in multivariate model were based on trend to significance in univariate model: revision before PJI, bacteremia at diagnosis, diabetes mellitus, duration of symptoms, enterococci, antimicrobial treatment strategy.

*b* Long-term rifampicin center: center where default antimicrobial strategy consisted of 12 weeks rifampicin combination therapy (see Table 1).
treated with clindamycin or flucloxacinill has a significant impact on outcome. A large RCT is warranted to definitively confirm the safety and effectivity of clindamycin and/or flucloxacinill monotherapy as appropriate alternatives for rifampicin combination therapy for staphylococcal PJI.

**Supplementary Data**

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Acknowledgments**

We are indebted to Josefien Hessels and Maxime Gerritsen who had a central role in importing patient data into the Castor database. We also acknowledge the support from local research coordinators Menno Benard, Jantsje Pasma, Bregje Thomassen, and Marjolein Schager for their help during the setup and follow up of the quality registry.

**Financial support.** This work was funded by an unrestricted grant from the Dutch health insurance company Zorg & Zekerheid (Grant Number ST.2015.53).

**Potential conflicts of interests.** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

**References**

1. Sabahi SA, Alvand A, Price AJ. Revision knee replacement for prosthetic joint infection: epidemiology, clinical outcomes and health-economic considerations. Knee 2021; 28:417–21.
2. RIVM. Report Postoperative Wound Infections The Netherlands 2015–2019. Available at: https://www.rivm.nl/documenten/referentiecijfers-powi-2019. Accessed 1 February 2022.
3. Manning L, Metcalf S, Clark B, et al. Clinical characteristics, etiology, and initial management strategy of newly diagnosed periprosthetic joint infection: a multicenter, prospective observational cohort study of 783 patients. Open Forum Infect Dis 2020; 7:ofaa068.
4. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:e1–25.
5. Nguyen S, Robineau O, Titicat M, et al. Influence of daily dosage and frequency of administration of rifampicin–levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections. Eur J Clin Microbiol Infect Dis 2015; 34:1675–82.
6. Vollmer JR, Rivera CG, Stevens RW, et al. Safety and tolerability of fluoroquinolones in patients with staphylococcal periprosthetic joint infections. Clin Infect Dis 2021; 73:850–6.
7. Scherê H, Gerritsen LM, Pijls BG, Van Asten SA, Visser LG, De Boer MGJ. Outcome of debridement, antibiotics, and implant retention for staphylococcal hip and knee prosthetic joint infections, focused on rifampicin use: a systematic review and meta-analysis. Open Forum Infect Dis 2021; 8:ofab298.
8. Aydin O, Ergen P, Ozturan B, Ozkan K, Arslan F, Vahaboglu H. Rifampicin-accompanied antibiotic regimens in the treatment of prosthetic joint infections: a frequentist and Bayesian meta-analysis of current evidence. Eur J Clin Microbiol Infect Dis 2021; 40:665–71.
9. Theil C, Schmidt-Braekling T, Goshueger G, et al. Clinical use of linezolid in peri-prosthetic joint infections—a systematic review. J Bone Joint Infect 2020; 6:7–16.
10. Karlisen OE, Bergen P, Brignes R, et al. Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial. J Orthop Surg Res 2020; 15:365.
11. Scherê H, van Hooven D, van de Sande M, et al. Outcome of acute staphylococcal prosthetic joint infection treated with debridement, implant retention and antimicrobial treatment with short duration of rifampicin. J Infect 2018; 76:498–500.
12. Dijkman NC, Kweekel DM, Balmforth C, et al. The simplified oral flucloxacinill absorption test: an accurate method to identify patients with inadequate oral flucloxacinill absorption. Neth J Med 2019; 77:255–60.
13. Tonnelier M, Bouras A, Joseph C, et al. Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France. BMC Infect Dis 2021; 21:174.
14. Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010; 54:88–92.
15. Leijtens B, Elbers JBW, Sturm PD, Kullberg BJ, Schreurs BW. Clindamycin-rifampicin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study. BMC Infect Dis 2017; 17:321.
16. Tevell S, Christenson B. Oral flucloxacinill for staphylococcal osteomyelitis: obsolate or underused? J Bone Joint Infect 2020; 5:25–7.
17. Vilchez F, Martinez-Pastor JC, Garcia-Ramiro S, et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin Microbiol Infect 2011; 17:439–44.
18. Mandell GL, Vest TK. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis 1972; 125:486–90.
19. Zeller V, Dzing-Ellia A, Kitiz MD, Zira JM, Mamoudy P, Desplaces N. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010; 54:88–92.
20. Leijtens B, Elbers JBW, Sturm PD, Kullberg BJ, Schreurs BW. Clindamycin-rifampicin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study. BMC Infect Dis 2017; 17:321.
21. Tevell S, Christenson B. Oral flucloxacinill for staphylococcal osteomyelitis: obsolete or underused? J Bone Joint Infect 2020; 5:25–7.